Nonpeptidomimetic farnesyltransferase inhibitor RPR-115135 increases cytotoxicity of 5-fluorouracil: Role of p53

Journal of Pharmacology and Experimental Therapeutics

Volumn 300, Issue 1, 2002, Pages 220-226

  Russo, Patrizia ^a,b   Ottoboni, Cristina ^a   Malacarne, Davide ^b   Crippa, Alessandra ^c   Riou, Jean Francois ^d   O'Connor, Patrick M ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c SANOFI   (France)

^d UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P53; RPR 115135; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL LINE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; TRANSGENE;

ALKYL AND ARYL TRANSFERASES; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; CELL SURVIVAL; CLONE CELLS; DNA FRAGMENTATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; INDOLES; PHENOTYPE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036138171     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.300.1.220     Document Type: Article

References (36)

1. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group Study
2. Lack of correlation between p53 overexpression and response to FURA-based chemotherapy in advanced colorectal cancer patients
3. Assessment of DNA damage in mammalian cells by filter elution methodology in cell growth and apoptosis: A practical approach
4. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
5. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems
6. Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors
7. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel
8. Cell lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard
9. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vineristine treatment
10. Anticancer drug targets: Growth factors and growth factors signaling
11. Multivariate data analysis using D-optimal designs, partial least squares, and response surface modelling: A directional approach for the analysis of farnesyltransferase inhibitors
12. Inhibition of Ras-targeted prenylation: Protein farnesyi transferase inhibitors revisited
13. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
14. Signal transduction from multiple Ras effectors
15. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption and ribonucleotide depletion
16. Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogens
17. p53 only ARF the story
18. Systemic adjuvant chemotherapy in colorectal cancer
19. Colorectal cancer
20. INK4A alleles in neoplasia
21. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Anticancer Drug Screen and correlations with the growth inhibitory potency of 123 anticancer agents
22. Phase-I combination trial of the farnesyltransferase inhibitor (FTI) R11577 with a 5FU/LV regimen in advanced colorectal (CRC) or pancreatic (PC) cancer
23. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia
24. Inhibition by uridine but not thyroidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: Evidence for the involvement of RNA perturbation
25. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells
26. Targeting the Ras signaling pathway: A rational, mechanism-based treatment for hematologic malignancies?
27. ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)
28. Cellular effects of a new farnesyltransferase inhibitor, RPR-115135, in a human isogenic colon cancer ceil line model system HCT-116
29. Cellular actions of a farnesyltransferase inhibitor, RPR-115135, in a human isogenic colon cancer ceil line system
30. New drugs in therapy of colorectal cancer: Preclinical studies
31. INK4a/ARF-mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
32. Where do we stand with 5-fluorouracil?
33. New directions in the treatment of colorectal cancer: A look to the future
34. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
35. AaF gene transfer in human mesothelioma cells